CD19-targeted CAR NK cell therapy achieves pr
<p>Researchers from <a href="http://www.MDAnderson.org">The University of Texas MD Anderson Cancer Center</a> reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived <a href="https://www.mdanderson.org/cancerwise/car-nk-therapy-offers-new-treatment-option-for-blood-cancers.h00-159379578.html">chimeric antigen receptor (CAR) natural killer (NK) cell therapy</a> targeting CD19. </p>
Source: eurekalert.org
